European Implantable Drug Delivery Devices Market Research Report
- Report Code: IM 1002
- Publish Date: Upcoming
The European Implantable Drug Delivery Market, mainly driven by a growing prevalence of target disease segments such as Prostate Cancer, diabetic retinopathy, chronic pain causing diseases, cardiovascular diseases, Colorectal Cancer, and a rapid aging global population was valued at $2.5 billion in 2013 and expected to be $3.2 billion by 2018, growing at a CAGR of 5.3%.
The report “European Implantable Drug Delivery Market forecast, 2012-2018 “analyzes the market of devices by segments such as Drug eluting stents, Infusion Pumps, Intraocular Implants, Brachytherapy Seeds, Contraceptive Implants.
Europe holds the second position in terms of value of the overall pharmaceutical market. The European pharmaceutical market was worth $228 billion in 2011, accounting for 26.8% of the global pharmaceuticals market. The industry invested Euro 27,500 million in R&D in 2011, provided direct employment to 660,000 Europeans, and generated three to four times more employment indirectly. However, the pharmaceutical markets in major five European countries - Germany, France, U.K., Italy, and Spain - grew at an average rate of 2.6% in 2011, due to the overall current grim economic condition in Europe and increasing competition from emerging nations.
The report also provides an extensive competitive landscaping of companies operating in Implantable Drug Delivery market. The main companies operating in Implantable Drug Delivery Market are Boston Scientific, Abbott Laboratories, Medtronic, Allergen INC, Merck, Bayer Pharma AG, Arrow International, Theragenics, Varian Medical Systems, and Eckert Ziegler.
Segment and country specific Company shares, News & Deals, M&A, segment specific pipeline products, product approvals and product recalls of the major companies have been detailed.
Customization Options:
With Market data, you can also customize MMM assessments that meet your Company’s specific needs. Customize to get comprehensive industry standard and deep dive analysis of the following parameters:
Product Analysis
- Usage pattern (in-depth trend analysis) of Implantable Drug Delivery products (Segment wise)
- Product Matrix which gives a detailed comparison of Implantable Drug Delivery product portfolio of each company mapped at country and sub segment level
- End-user Adoption rate analysis of the products (Segment wise and Country wise)
- Comprehensive coverage of Product approvals, Pipeline products and Product recalls
Epidemiology Data
- Country specific Prevalence of Prostate Cancer, Breast and female genital organs Cancers, Lung and pleura Cancers, Head and neck cancers, Colorectal Cancer, Spine Cancer and Brain Cancer
- Country specific Patient pool of Prostate Cancer, Breast and female genital organs Cancers, Lung and pleura Cancers, Head and neck cancers, Colorectal Cancer, Spine Cancer and Brain Cancer
- Disease progression (Pattern analysis)
Pharmacists Forum
- Fast turn-around analysis of Pharmacists response to market events and trends
- Pharmacists opinion about Implantable Drug Delivery products from different companies
- Pharmacists qualitative inputs on epidemiology data
- Pattern analysis of usage of drugs by physicians
Brand/Product Perception Matrix
- Comprehensive study of customers perception and behavior through our inbuilt social connect tool checking the virality and tonality of blogs
- Analysis of overall brand usage and familiarity and brand advocacy distribution (Detractor/Neutral/Familiar)
Pricing Trends
- Cost Analysis of Drug Delivery Implants in Various Countries.
- Prostate Cancer, diabetic retinopathy, Colorectal Cancer, cardiovascular implants procedural investment in major countries.
Competitive Intelligence
- The company share analysis of Implantable Drug Delivery Systems for the top players of the market in the Asia.
- The crucial developments and strategies of companies inculcating in their portfolio for Implantable Drug Delivery Systems.
Please fill in the form below to receive a free copy of the Summary of this Report
Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
| PRODUCT TITLE | PUBLISHED | |
|---|---|---|
|
|
North American Drug Delivery Devices Market The North American Drug Delivery Devices Market was valued at $16 billion in 2013 and expected to be $110 billion by 2018, growing at a CAGR of 8.9%. The report “North American Drug Delivery Devices Market Forecast, 2012-2018“analyzes the market of Drug Delivery Devices by 9 technologies such as oral, transdermal, respiratory, injectable, implantable, transmucosal, nasal, ocular and topical drug delivery devices. The main companies operating in Drug Delivery Devices market and extensively covered in this report are SkyePharma Plc (U.K.), Ypsomed Holding AG (Switzerland), and GSK (U.K.). |
Upcoming |
|
|
European Drug Delivery Devices Market The European Drug Delivery Devices Market was valued at $45 billion in 2013 and expected to be $63 billion by 2018, growing at a CAGR of 8.3%. The report “European Drug Delivery Devices Market Forecast, 2012-2018“analyzes the market of Drug Delivery Devices by 9 technologies such as oral, transdermal, respiratory, injectable, implantable, transmucosal, nasal, ocular and topical drug delivery devices. The main companies operating in Drug Delivery Devices market and extensively covered in this report are SkyePharma Plc (U.K.), Ypsomed Holding AG (Switzerland), and GSK (U.K.). |
Upcoming |
|
|
Asian Drug Delivery Devices Market The Asian Drug Delivery Devices Market was valued at $28 billion in 2013 and expected to be $50 billion by 2018, growing at a CAGR of 12.6%. The report “Asian Drug Delivery Devices Market Forecast, 2012-2018“analyzes the market of Drug Delivery Devices by 9 technologies such as oral, transdermal, respiratory, injectable, implantable, transmucosal, nasal, ocular and topical drug delivery devices. The main companies operating in this market and extensively covered in this report are 3M Company, Alkermes, Baxter International, Inc., Becton, Dickinson & Co., The Dow Chemical Company, Johnson & Johnson, Nektar Therapeutics, SkyePharma PLC,. |
Upcoming |
